Analyst Jason McCarthy of Maxim Group maintained a Buy rating on Aprea Therapeutics, retaining the price target of $10.00.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Jason McCarthy has given his Buy rating due to a combination of factors related to Aprea Therapeutics’ promising advancements in its synthetic lethality programs. The company is making significant progress with its lead programs, ATRN-119 and APR-1051, which are showing favorable safety profiles and early signs of efficacy in clinical trials. Aprea’s ATRN-119, an ATR inhibitor, has demonstrated stable disease and some tumor shrinkage in heavily pretreated patients, which is notable given the continuous dosing strategy that sets it apart from competitors who have faced toxicity issues.
Moreover, the WEE1 inhibitor APR-1051 has shown positive results in early trials, with stable disease observed in several patients. The company’s financial position, with sufficient funds to support operations into late 2026, allows it to continue its clinical development efforts and pursue potential combination therapies. These factors, combined with the anticipation of key data events in 2026, underpin McCarthy’s confidence in Aprea’s potential, leading to his Buy rating.
McCarthy covers the Healthcare sector, focusing on stocks such as SCYNEXIS, Neuphoria Therapeutics, and OS Therapies Incorporated. According to TipRanks, McCarthy has an average return of -14.4% and a 33.20% success rate on recommended stocks.